Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00974974 · ClinicalTrials.gov registry record · Phase 3
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
A Phase 3 study, sponsored by Impax Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 471
- Enrollment target
NCT00974974 is a Phase 3 study that has completed, run by Impax Laboratories. The registered enrollment target is 471 participants.
The verdict
NCT00974974, a Phase 3 study, has completed, sponsored by Impax Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 471 participants
- Enrollment target
Study Summary
This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease.
Interventions
- DRUG IPX066
- DRUG IR CD-LD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 471 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00974974
The ClinicalTrials.gov registry entry for NCT00974974 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 471 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Impax Laboratories, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IPX066 is the first listed.
NCT00974974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00974974 about?
NCT00974974 is a clinical study titled "A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).". This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease.
What is the current status of trial NCT00974974?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 471 participants. The study started on 2009-09. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00974974?
The interventions under investigation include: IPX066 (DRUG), IR CD-LD (DRUG).
Who is sponsoring clinical trial NCT00974974?
This trial is sponsored by Impax Laboratories, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.